| Abstrakt: |
The skin is the body's largest organ and creates the initial impression when interacting with others. Thus, dermatological conditions can have a profound impact on the quality of life, affecting both mental and physical well-being. The increasingly common use of new biological therapies in dermatology for conditions such as psoriasis, atopic dermatitis, and chronic urticaria represents hope for these patients, significantly improving their quality of life. Interleukin -17, -23, -4, -13 inhibitors (ixekizumab, guselkumab, tildrakizumab, secukinumab, dupilumab) target molecules involved in the onset of these diseases and manage to provide patients with sustained efficacy over time, with an optimal safety profile. Results have been quantified using scores such as PASI (Psoriasis Area and Severity Index), DLQI (Dermatology Life Quality Index), GAD-7 (Generalized Anxiety Disorder scale-7), analyzed by specialist physicians, revealing significant improvements following biological therapies. [ABSTRACT FROM AUTHOR] |
